Anemia MS3 Mandernach
Anemia MS3 Mandernach
Anemia MS3 Mandernach
Cases
• Initial Labs:
– Hemoglobin 7.9 gm/dL
– HCT 23.9%
– WBC 4000/mm3 with a normal differential
– Platelet 138,000/mm3
• MCV 114
• Uncorrected Retic count 14.2%
• LDH 2343 U/L
• Bilirubin 4.3mg/dL
• Direct bili .8mg/dL
• The peripheral blood smear reveals
macrovalocytes, polychromasia, and an
occasional nucleated red blood cell.
Case 1
Case 1
• Treatment:
– Prednisone
– Splenectomy
– Rituximab (monoclonal antibody)
– Immunosuppressive agents
• Cytoxan, imuran, cyclosporin
– Danazol
– Plasma exchange
Case 1
• Labs:
– HCT 31-34%
– Hgb 10.6-11.4gm/dL
– PLT 232-312K/mm3
– WBC 6500-8000/mm3 with a normal differential
– MCV 72-74 cubic microns
• Differential Diagnosis:
– Iron deficiency anemia
• Noncompliance, inadequate dosing, incorrect
formulation.
– Beta thalassemia
– Alpha thalassemia
– Anemia of chronic inflammation/disease
– Sideroblastic anemia
– Lead
• What additional lab tests would you like to order?
Case 2
• Routine labs:
– WBC = 1700/mm3
– Hgb = 5.6 gm/dL
– HCT 18.2%
– Platelet – 12,000/mm3
• What important piece of laboratory
information is missing from the WBC?
Case 3
• Labs:
– WBC 5600/mm3, normal differential
– HCT 16.3%
– Hgb 5.3 gm/dL
– Platelets 21,000/mm3
– PT 11 sec
– PTT 29 sec
Case 4
• Labs:
– Creatinine 2.4 mg/dL
– LDH 3000 U/L
– Bili 3.2 mg/dL, mostly indirect
– Reticulocyte count 6.2%
– Haptoglobin <10mg/dL
– Urine: 2+ hemoglobin, neg RBC
Case 4
Case 4
• Pathophysiology:
– Typically an inhibitor against ADAMTS- 13, a vWF
cleaving to protease leading to accumulation of
High Molecular Weight vWF multimers leading to
small vessel thrombosis and microangiopathic
hemolytic anemia.
– Plasmapheresis:
• Removes the offending antibody
• Supplies the deficient ADAMTS-13
Case 4
Case 5
• Differential Diagnosis:
– Anemia of renal failure
– Iron deficiency anemia
– Thalassemia
– Lead poisoning
– Myelodysplasia
– Mixed microcytic and macrocytic anemia.
• You request one more study to support your
suspicion?
Case 5
• Skeletal survey
• Multiple lytic lesions throughout the skeleton
NORMAL
Case 6: Myeloma
1 2
*
+ -
Case 6: Density Scan
+ -
Albumin
-1 -2
Case 6
• Immunofixation (IFE):
– Proteins are fractioned on electrophoretic strips:
• Each lane overlaid with monospecific antisera against
IgG, IgA, IgM, and light chains
• Immunoglobulins are precipitated by antisera
– Wash away nonprecipitated proteins
• Precipitated proteins are stained
Case 6: Normal IFE
+ -
Albumin
component”
-1 -2
Our patient
Case 6
Case 6: Stage III Multiple Myeloma
• Progression of symptoms
• Blood in stool
• Other medications or toxins, including EToH
• Prior history of anemia, prior CBC’s
• Other constitutional symptoms, recent illness
• Family history
• Diet
• Craving ice, starch, or dirt
Case A
• Iron studies:
– Fe 14 ug/dL
– TIBC 426 ug/dL
– % sat 3%
– Ferritin 10ng/mL
• Corrected reticulocyte count 1.1%
• Clinical findings:
– Insidious onset.
– Glossitis, weight loss, pale yellow skin.
– Neurologic manifestations:
• Loss of position or vibratory sense.
• Can progress to spastic ataxia.
• May occur with mild anemia and may be irreversible.
– Psychiatric disorders can occur without evidence of
hematologic abnormalities.
• Hallucinations, dementia, psychosis, “megaloblastic mania”.
• May be irreversible.
Case B: Vitamin B12 Deficiency
• Lab findings:
– Cobalamin <200ng/L.
– If low-normal (200-350ng/L), check homocysteine
and MMA.
• Both elevated in Vitamin B12 deficiency.
– Methylmalonic acid level is more sensitive than
low-normal cobalamin alone.
– Pernicious anemia:
• Autoantibodies to parietal cells or intrinsic factor (50-
70% sensitive, 100% specific).
Case B: Vitamin B12 Deficiency
• Treatment:
– Parenteral:
• 1000ug IM for 5 days followed by weekly for 4-5 weeks, then
monthly.
– Oral:
• 1000-2000ug/day.
• Reticulocytosis in 3-5 days, blood counts normalize
by 2-3 months.
• Folate may correct the anemia but not the
neuropsychiatric manifestations, so you must check
both prior to administration of folate.